VTVT
NASDAQvTv Therapeutics Inc.
News · 26 weeks33+250%
2026-04-192026-10-11
Mix1590d
- Other10(67%)
- SEC Filings3(20%)
- Dividends1(7%)
- Leadership1(7%)
Latest news
25 items- PRiOnctura appoints Paul Sekhri as Chair of its Board of DirectorsPaul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercializationAppointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolledStrengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with immediate effect. Paul’s career spa
- PRvTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026HIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that Chief Medical Officer Thomas Strack, M.D., Ph.D., presented research spotlighting hypoglycemia-related burdens among adults with T1D using automated insulin delivery (AID) systems at the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) in Philadelphia, PA. Cadisegliatin is a potential first-in-class, liver-selective glucokinase activator (GKA) being evaluated as an oral adjunctive therapy to insulin for the treatment of T1D. "A Cum
- SECAmendment: SEC Form SCHEDULE 13G/A filed by vTv Therapeutics Inc.SCHEDULE 13G/A - vTv Therapeutics Inc. (0001641489) (Subject)
- PRvTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseHIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to HPPD, the Company’s oral, first-in-class Nrf2/Bach1 modulator. HPPD is being investigated as a treatment for sickle cell disease. "The FDA’s Orphan Drug Designation reinforces both the urgency of the unmet need in this devastating disease and the opportunity to bring forward potential new therapeutic approaches," said Paul Sekhri, Chairman, President, and CEO of vTv Therape
- SECSEC Form 8-K filed by vTv Therapeutics Inc.8-K - vTv Therapeutics Inc. (0001641489) (Filer)
- PRvTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET. To register, click here. The event will feature leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego), Klara Klein, MD, PhD (University of North Carolina at Chapel Hill School of Medicine), and acclaimed cellist and T1D advocate Alisa Weilerstein. Together, they will join company management to discuss: Ongoi
- PRvTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)HIGH POINT, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1) study. A total of 166 patients have been randomized in the study evaluating cadisegliatin, a potential first-in-class oral, liver-selective glucokinase activator that has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to insulin for the treatment of T1D. "Completing enrollme
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted at an exercise price of $31.44 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on th
- PRvTv Therapeutics to Participate in September Investor ConferencesHIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Fireside Chat and one-on-one investor meetingsDate: Wednesday, September 16, 2026Time: 10:00-10:30 AM ETLocation: New York, NYWebcast Link 5th Annual ROTH Healthcare Opportunities Conference Format: One-on-one investor meetings Date: Tuesday, September 29, 2026 About vTv TherapeuticsvTv Therapeutics is a late-s
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted at an exercise price of $31.48 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the
- SECSEC Form 10-Q filed by vTv Therapeutics Inc.10-Q - vTv Therapeutics Inc. (0001641489) (Filer)
- SECvTv Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - vTv Therapeutics Inc. (0001641489) (Filer)
- PRvTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePhase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes
- SECAmendment: SEC Form SCHEDULE 13G/A filed by vTv Therapeutics Inc.SCHEDULE 13G/A - vTv Therapeutics Inc. (0001641489) (Subject)
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 23,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have a weighted average exercise price of $31.95 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have a weighted average exercise price of $34.15 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the
- ANALYSTRodman & Renshaw initiated coverage on vTv Therapeutics with a new price targetRodman & Renshaw initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $67.00
- INSIDERSEC Form 4 filed by Director Baker Bros. Advisors Lp4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- SECvTv Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - vTv Therapeutics Inc. (0001641489) (Filer)
- INSIDERSEC Form 4 filed by Director Spiegelman Daniel K4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- INSIDERSEC Form 4 filed by Director Akkaraju Srinivas4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Anne M.4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- INSIDERSEC Form 4 filed by Director Al-Marzooqi Fahed4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- SECSEC Form DEFA14A filed by vTv Therapeutics Inc.DEFA14A - vTv Therapeutics Inc. (0001641489) (Filer)
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $34.30 per share, which is equal to the closing price of the Company's common stock on June 1, 2026. Each option will vest ov
VTVT FAQ
7 questionsWhat does vTv Therapeutics Inc. do?
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and...Where does VTVT stock trade?
vTv Therapeutics Inc. (VTVT) is listed on NASDAQ.What sector and industry is VTVT in?
vTv Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did vTv Therapeutics Inc. go public?
vTv Therapeutics Inc. (VTVT) completed its IPO in 2015.What are analysts saying about VTVT?
vTv Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy on 2026-06-30.What companies are similar to VTVT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VTVT side-by-side with any of them on Quantisnow.How can I track VTVT on Quantisnow?
Quantisnow aggregates vTv Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VTVT to receive live email and push alerts on every new disclosure.